佐力药业(300181) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥616,624,658.40, representing a 35.97% increase compared to the same period last year[2]. - Net profit attributable to shareholders for the same period was ¥125,426,028.33, up 40.61% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was ¥122,964,581.10, reflecting a 41.17% increase from the previous year[2]. - Total operating revenue for the period reached CNY 2,044,879,347.76, a significant increase of 39.5% compared to CNY 1,464,947,132.50 in the previous period[20]. - Net profit for the period was CNY 427,382,283.28, representing a 46.0% increase from CNY 292,583,698.54 in the same period last year[21]. - Basic earnings per share increased to CNY 0.6018, compared to CNY 0.4090 in the previous period, reflecting a growth of 47.0%[22]. - Comprehensive income for the period was CNY 393,943,478.14, compared to CNY 170,623,591.54 in the previous period, reflecting a substantial increase of 130.7%[22]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,872,439,027.99, a 6.77% increase from the end of the previous year[2]. - The company's equity attributable to shareholders decreased to ¥2,599,700,232.89, down 4.73% from the end of the previous year[2]. - Total liabilities increased to CNY 1,231,183,875.67, compared to CNY 853,092,322.35 in the previous period, indicating a growth of 44.3%[21]. - Deferred income rose to CNY 21,764,990.99 from CNY 19,896,586.81, marking an increase of 9.3%[21]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥214,125,849.27, showing a decline of 4.39% compared to the same period last year[2]. - The net cash flow from operating activities for Q3 2024 was ¥214,125,849.27, a decrease of 4% compared to ¥223,951,981.61 in Q3 2023[24]. - The total cash outflow from operating activities amounted to ¥1,699,968,873.74, up 20.5% from ¥1,410,316,284.08 in the same period last year[24]. - Cash inflow from investment activities was ¥152,158,992.83, significantly higher than ¥41,035,518.00 in Q3 2023, marking an increase of 270%[24]. - Cash inflow from financing activities reached ¥377,680,678.00, up 42.3% from ¥265,369,428.54 in Q3 2023[24]. - The company paid ¥315,089,308.18 in dividends and interest, an increase of 43.5% compared to ¥219,402,461.84 in Q3 2023[24]. Operational Highlights - Accounts receivable increased by 58.92% to ¥751,449,300.00, primarily due to increased sales revenue[7]. - The company reported a significant increase in prepayments, which rose by 506.32% to ¥24,985,700.00, attributed to higher procurement and R&D expenses[7]. - Short-term borrowings increased by 87.32% to ¥361,647,900.00, indicating a rise in financing activities[7]. - The revenue from the Wuling series increased by 24.88% year-on-year, driven by a 30.24% increase in sales volume and a 22.67% increase in sales amount for Wuling capsules, and a 37.05% increase in sales volume and a 36.90% increase in sales amount for Lingze tablets[9]. - The sales revenue from traditional Chinese medicine decoction pieces grew by 51.24% year-on-year, while the sales revenue from Chinese medicine formula granules surged by 175.96% year-on-year due to an increase in registered varieties[9]. - The operating costs for the year-to-date period reached 785.11 million yuan, an increase of 70.93% year-on-year, primarily due to rising costs associated with increased sales revenue[9]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 36,613[11]. - The largest shareholder, Yu Youqiang, holds 18.52% of the shares, with 64.5 million shares pledged[12]. - The total number of restricted shares held by major shareholders at the beginning of the period was 1,378,901, with 601,515 shares released and 262,879 shares added, resulting in 1,040,265 restricted shares at the end of the period[14]. - The controlling shareholder, Yu Youqiang, has pledged 64,500,000 shares, accounting for 49.66% of his holdings and 9.20% of the company's total share capital[15]. Future Plans - The company plans to continue investing in projects such as the "Intelligent Traditional Chinese Medicine Production Base" and "Innovative Pharmaceutical Industrialization Project" to support future growth[7]. - The company plans to implement an equity incentive plan funded by the share repurchase[16]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[16].